Vericel Corporation files BLA at FDA for MACI to treat symptomatic cartilage defects of the knee
Vericel Corporation announced that it has submitted a Biologics License Application (BLA) to the FDA for MACI (matrix applied characterized autologous cultured chondrocytes), the company's investigational autologous cellular product intended for the treatment of symptomatic cartilage defects of the knee in adult patients.
MACI is a third-generation autologous chondrocyte implant (ACI) product intended for the treatment of symptomatic cartilage defects in the knee in adult patients. MACI is an autologous implant consisting of cultured chondrocytes seeded onto a resorbable Type I/III collagen membrane. Autologous cultured chondrocytes are human-derived cells which are obtained from the patient's own cartilage for the manufacture of MACI.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
2 mins